×
About 600 results

ALLMedicine™ Drug Eruptions Center

Research & Reviews  281 results

Eczematous Drug Eruptions.
https://doi.org/10.1007/s40257-021-00586-8 10.1046/j.1468-3083.2000.00159-5.x 10.1046/j.1365-2133.1998.02313.x 10.2340/00015555-0143 10.1007/s40257-017-0296-7 10.1177/1203475420917387 10.1080/09546634.2016.1230173 10.1136/gutjnl-2012-302853 10.1111/jdv.16246 10.1159/000235582 10.1097/MIB.0000000000000342 10.1111/1346-8138.14816 10.1016/j.crohns.2013.10.013 10.3389/fphar.2019.00282 10.7326/M15-0729 10.1111/j.1365-2133.2009.09329.x 10.1111/1346-8138.13762 10.1111/bjd.16126 10.1038/s41467-017-02466-4 10.1290/0501008.1 10.1111/cea.12217 10.4049/jimmunol.1800013 10.2147/JIR.S215196 10.1111/bjd.17779 10.1111/1346-8138.13622 10.1080/14712598.2020.1727439 10.1111/jdv.15156 10.1016/j.jdcr.2019.09.005 10.1016/j.jaip.2020.06.064 10.1001/jamadermatol.2020.1019 10.2147/CCID.S165605 10.1111/pde.13342 10.1111/cod.12772 10.1038/s41467-020-17670-y 10.1007/s40257-017-0336-3 10.1016/j.jaad.2019.06.035 10.1001/jamadermatol.2015.1916 10.1016/j.jaad.2020.03.132 10.1111/jdv.16311 10.1007/s11864-020-0721-7 10.3346/jkms.2019.34.e186 10.1016/j.jaad.2018.10.062 10.1007/s40257-018-0376-3 10.1016/j.ejca.2016.02.010 10.1097/CCO.0000000000000290 10.1097/PAS.0000000000000900 10.1016/j.jaad.2018.05.035 10.1007/s40257-018-0384-3 10.3816/CLC.2009.n.004 10.1038/nrc1970 10.1016/j.jaad.2006.09.005 10.1093/annonc/mdi279 10.1111/j.1468-3083.2009.03446.x 10.1111/j.1365-4632.2011.05082.x 10.1684/ejd.2011.1468 10.1111/j.1365-2230.2012.04415.x 10.1126/scitranslmed.3005886 10.1200/JCO.2002.20.1.110 10.1007/s11523-009-0107-z 10.1002/cia2.12075 10.3109/0284186X.2014.923583 10.1002/cncr.27505 10.1200/JCO.2004.08.116 10.1111/j.1365-2133.2011.10777.x 10.1097/DAD.0000000000000253 10.1159/000321367 10.1159/000104423 10.1001/jamadermatol.2013.938 10.1177/1203475415595775 10.1097/MCG.0b013e318228b5f6 10.1111/j.1365-2133.2004.05957.x 10.1159/000353160 10.1016/j.jcv.2014.04.012 10.1016/j.ad.2013.12.023 10.1016/j.jhep.2011.08.006 10.2340/00015555-2174 10.1159/000075046 10.1056/NEJMoa1501481 10.1155/2009/651952 10.1046/j.1365-2133.2002.04897.x 10.1001/archderm.140.2.215 10.1001/archderm.141.1.102-b 10.1097/MJT.0000000000001071 10.1097/ACI.0000000000000181 10.1007/s40266-017-0483-5 10.2165/00128071-200910020-00001 10.1038/sj.jid.5701018 10.1001/jamadermatol.2013.511 10.1111/cod.12832 10.21037/atm.2017.07.16 10.3109/08923973.2013.797992 10.1001/archderm.1985.01660040106021 10.1111/j.1365-2133.1974.tb13074.x 10.1016/j.jaad.2020.05.015 10.1159/000247363 10.1159/000247370 10.1111/j.1600-0536.1994.tb00651.x 10.1111/j.1365-4632.2010.04579.x 10.1016/j.jaad.2010.12.034 10.1136/bcr-2019-229596 10.1111/j.1525-1470.2011.01717.x 10.1177/039463201402700117 10.1111/j.1365-2133.2004.06158.x 10.1136/bcr-2012-008001 10.1016/j.ijwd.2018.03.004 10.1503/cmaj.121036 10.1001/jamadermatol.2014.109 10.1001/archderm.142.2.213 10.1016/j.jaci.2016.09.023 10.1111/j.1468-3083.1999.tb01017.x 10.1111/j.1600-0536.1989.tb03142.x 10.1001/archderm.1981.01650050029015 10.4103/0019-5154.96191 10.1111/j.1600-0536.1987.tb01455.x 10.1016/j.ad.2017.02.011 10.1007/s13300-012-0014-7 10.1136/postgradmedj-2018-136378 10.2340/00015555-3539 10.1111/ced.14293 10.1111/j.1600-0536.1993.tb03365.x 10.1111/j.1600-0536.2012.02066.x 10.1111/ajd.12502 10.1111/ajd.12509 10.2165/11539080-000000000-00000 10.1007/s12016-018-8686-z 10.1111/j.1365-4632.2011.05104.x 10.1016/0738-081X(93)90153-4 10.1111/j.1600-0536.1975.tb05372.x 10.1111/j.1600-0536.2009.01688.x 10.1111/j.1600-0536.1981.tb04070.x 10.1046/j.1440-0960.2001.00470.x 10.1111/j.1600-0536.1991.tb01657.x 10.1111/j.0105-1873.2004.00445.x 10.1007/978-3-030-27099-5 10.1111/j.0105-1873.2004.00294.x 10.1111/j.1600-0536.1996.tb02135.x 10.1159/000246167 10.1016/j.clindermatol.2010.11.007 10.1159/000018408 10.1016/0190-9622(91)70024-V 10.1111/j.1398-9995.2011.02666.x 10.1111/j.1600-0536.1977.tb03708.x 10.1517/14740338.4.5.837 10.4103/0378-6323.82424 10.2310/6620.2008.08019 10.1016/j.jaad.2012.09.013 10.1517/14740338.6.4.431 10.1016/0190-9622(95)91271-1 10.1007/s40264-019-00806-5 10.1111/j.1365-2230.1993.tb00968.x 10.1111/j.1600-0536.1992.tb00859.x 10.1159/000249200 10.1001/archderm.1990.01670270049008 10.1111/j.1600-0536.1983.tb04376.x 10.1016/j.ad.2013.01.010 10.1016/j.jaip.2018.09.029 10.1097/DER.0000000000000208 10.18176/jiaci.0138 10.1111/j.1346-8138.1990.tb01631.x 10.1016/j.tox.2004.12.024 10.1007/s11882-014-0442-8 10.3109/1547691X.2015.1008656 10.1016/0091-6749(86)90175-2 10.1111/cod.12990 10.1034/j.1600-0781.2002.02778.x 10.1200/JCO.2015.66.1389
American Journal of Clinical Dermatology; Blum AE, Burgin S

Feb 15th, 2021 - Eczematous drug eruptions are a heterogenous group of skin reactions that resemble eczema both clinically and histologically. We reviewed the literature and cataloged the systemically administered medications that cause these eruptions, along with...

Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-relat...
https://doi.org/10.1016/j.clindermatol.2020.06.013
Clinics in Dermatology; McNamara K, Hughes OB et. al.

Dec 20th, 2020 - Cutaneous manifestations of drug reactions are common yet vary widely in their appearance and degree of internal organ involvement. Serum sickness--like reactions, symmetrical drug-related intertriginous and flexural exanthem, granulomatous drug e...

Pediatric drug eruptions.
https://doi.org/10.1016/j.clindermatol.2020.06.014
Clinics in Dermatology; Nguyen E, Gabel CK et. al.

Dec 20th, 2020 - Drug eruptions in children are common but in general less studied than their adult counterparts. Aside from having significant impact on the child's health and quality of life, these reactions can limit what medications the patient can receive in ...

Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions.
https://doi.org/10.1016/j.clindermatol.2020.06.010
Clinics in Dermatology; Cheraghlou S, Levy LL

Dec 20th, 2020 - Drug reactions are among the most common reasons for inpatient dermatology consultation. These reactions are important to identify because discontinuation of the offending agent may lead to disease remission. With the rising use of immunomodulator...

A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883102
Dermatologic Therapy; Najar Nobari N, Seirafianpour F et. al.

Dec 10th, 2020 - Most of drugs could have certain mucocutaneous reactions and COVID-19 drugs are not an exception that we focused. We systematically reviewed databases until August 15, 2020 and among initial 851 articles, 30 articles entered this study (20 case re...

see more →

Guidelines  1 results

Genital Ulcers: Differential Diagnosis and Management
https://www.aafp.org/afp/2020/0315/p355.html
American Family Physician; Roett MA,et al

Mar 14th, 2020 - Genital ulcers may be located on the vagina, penis, and anorectal or perineal areas and may be infectious or noninfectious. Herpes simplex virus is the most common cause of genital ulcers in the United States. A diagnosis of genital herpes simplex...

see more →

Clinicaltrials.gov  285 results

Eczematous Drug Eruptions.
https://doi.org/10.1007/s40257-021-00586-8 10.1046/j.1468-3083.2000.00159-5.x 10.1046/j.1365-2133.1998.02313.x 10.2340/00015555-0143 10.1007/s40257-017-0296-7 10.1177/1203475420917387 10.1080/09546634.2016.1230173 10.1136/gutjnl-2012-302853 10.1111/jdv.16246 10.1159/000235582 10.1097/MIB.0000000000000342 10.1111/1346-8138.14816 10.1016/j.crohns.2013.10.013 10.3389/fphar.2019.00282 10.7326/M15-0729 10.1111/j.1365-2133.2009.09329.x 10.1111/1346-8138.13762 10.1111/bjd.16126 10.1038/s41467-017-02466-4 10.1290/0501008.1 10.1111/cea.12217 10.4049/jimmunol.1800013 10.2147/JIR.S215196 10.1111/bjd.17779 10.1111/1346-8138.13622 10.1080/14712598.2020.1727439 10.1111/jdv.15156 10.1016/j.jdcr.2019.09.005 10.1016/j.jaip.2020.06.064 10.1001/jamadermatol.2020.1019 10.2147/CCID.S165605 10.1111/pde.13342 10.1111/cod.12772 10.1038/s41467-020-17670-y 10.1007/s40257-017-0336-3 10.1016/j.jaad.2019.06.035 10.1001/jamadermatol.2015.1916 10.1016/j.jaad.2020.03.132 10.1111/jdv.16311 10.1007/s11864-020-0721-7 10.3346/jkms.2019.34.e186 10.1016/j.jaad.2018.10.062 10.1007/s40257-018-0376-3 10.1016/j.ejca.2016.02.010 10.1097/CCO.0000000000000290 10.1097/PAS.0000000000000900 10.1016/j.jaad.2018.05.035 10.1007/s40257-018-0384-3 10.3816/CLC.2009.n.004 10.1038/nrc1970 10.1016/j.jaad.2006.09.005 10.1093/annonc/mdi279 10.1111/j.1468-3083.2009.03446.x 10.1111/j.1365-4632.2011.05082.x 10.1684/ejd.2011.1468 10.1111/j.1365-2230.2012.04415.x 10.1126/scitranslmed.3005886 10.1200/JCO.2002.20.1.110 10.1007/s11523-009-0107-z 10.1002/cia2.12075 10.3109/0284186X.2014.923583 10.1002/cncr.27505 10.1200/JCO.2004.08.116 10.1111/j.1365-2133.2011.10777.x 10.1097/DAD.0000000000000253 10.1159/000321367 10.1159/000104423 10.1001/jamadermatol.2013.938 10.1177/1203475415595775 10.1097/MCG.0b013e318228b5f6 10.1111/j.1365-2133.2004.05957.x 10.1159/000353160 10.1016/j.jcv.2014.04.012 10.1016/j.ad.2013.12.023 10.1016/j.jhep.2011.08.006 10.2340/00015555-2174 10.1159/000075046 10.1056/NEJMoa1501481 10.1155/2009/651952 10.1046/j.1365-2133.2002.04897.x 10.1001/archderm.140.2.215 10.1001/archderm.141.1.102-b 10.1097/MJT.0000000000001071 10.1097/ACI.0000000000000181 10.1007/s40266-017-0483-5 10.2165/00128071-200910020-00001 10.1038/sj.jid.5701018 10.1001/jamadermatol.2013.511 10.1111/cod.12832 10.21037/atm.2017.07.16 10.3109/08923973.2013.797992 10.1001/archderm.1985.01660040106021 10.1111/j.1365-2133.1974.tb13074.x 10.1016/j.jaad.2020.05.015 10.1159/000247363 10.1159/000247370 10.1111/j.1600-0536.1994.tb00651.x 10.1111/j.1365-4632.2010.04579.x 10.1016/j.jaad.2010.12.034 10.1136/bcr-2019-229596 10.1111/j.1525-1470.2011.01717.x 10.1177/039463201402700117 10.1111/j.1365-2133.2004.06158.x 10.1136/bcr-2012-008001 10.1016/j.ijwd.2018.03.004 10.1503/cmaj.121036 10.1001/jamadermatol.2014.109 10.1001/archderm.142.2.213 10.1016/j.jaci.2016.09.023 10.1111/j.1468-3083.1999.tb01017.x 10.1111/j.1600-0536.1989.tb03142.x 10.1001/archderm.1981.01650050029015 10.4103/0019-5154.96191 10.1111/j.1600-0536.1987.tb01455.x 10.1016/j.ad.2017.02.011 10.1007/s13300-012-0014-7 10.1136/postgradmedj-2018-136378 10.2340/00015555-3539 10.1111/ced.14293 10.1111/j.1600-0536.1993.tb03365.x 10.1111/j.1600-0536.2012.02066.x 10.1111/ajd.12502 10.1111/ajd.12509 10.2165/11539080-000000000-00000 10.1007/s12016-018-8686-z 10.1111/j.1365-4632.2011.05104.x 10.1016/0738-081X(93)90153-4 10.1111/j.1600-0536.1975.tb05372.x 10.1111/j.1600-0536.2009.01688.x 10.1111/j.1600-0536.1981.tb04070.x 10.1046/j.1440-0960.2001.00470.x 10.1111/j.1600-0536.1991.tb01657.x 10.1111/j.0105-1873.2004.00445.x 10.1007/978-3-030-27099-5 10.1111/j.0105-1873.2004.00294.x 10.1111/j.1600-0536.1996.tb02135.x 10.1159/000246167 10.1016/j.clindermatol.2010.11.007 10.1159/000018408 10.1016/0190-9622(91)70024-V 10.1111/j.1398-9995.2011.02666.x 10.1111/j.1600-0536.1977.tb03708.x 10.1517/14740338.4.5.837 10.4103/0378-6323.82424 10.2310/6620.2008.08019 10.1016/j.jaad.2012.09.013 10.1517/14740338.6.4.431 10.1016/0190-9622(95)91271-1 10.1007/s40264-019-00806-5 10.1111/j.1365-2230.1993.tb00968.x 10.1111/j.1600-0536.1992.tb00859.x 10.1159/000249200 10.1001/archderm.1990.01670270049008 10.1111/j.1600-0536.1983.tb04376.x 10.1016/j.ad.2013.01.010 10.1016/j.jaip.2018.09.029 10.1097/DER.0000000000000208 10.18176/jiaci.0138 10.1111/j.1346-8138.1990.tb01631.x 10.1016/j.tox.2004.12.024 10.1007/s11882-014-0442-8 10.3109/1547691X.2015.1008656 10.1016/0091-6749(86)90175-2 10.1111/cod.12990 10.1034/j.1600-0781.2002.02778.x 10.1200/JCO.2015.66.1389
American Journal of Clinical Dermatology; Blum AE, Burgin S

Feb 15th, 2021 - Eczematous drug eruptions are a heterogenous group of skin reactions that resemble eczema both clinically and histologically. We reviewed the literature and cataloged the systemically administered medications that cause these eruptions, along with...

Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-relat...
https://doi.org/10.1016/j.clindermatol.2020.06.013
Clinics in Dermatology; McNamara K, Hughes OB et. al.

Dec 20th, 2020 - Cutaneous manifestations of drug reactions are common yet vary widely in their appearance and degree of internal organ involvement. Serum sickness--like reactions, symmetrical drug-related intertriginous and flexural exanthem, granulomatous drug e...

Pediatric drug eruptions.
https://doi.org/10.1016/j.clindermatol.2020.06.014
Clinics in Dermatology; Nguyen E, Gabel CK et. al.

Dec 20th, 2020 - Drug eruptions in children are common but in general less studied than their adult counterparts. Aside from having significant impact on the child's health and quality of life, these reactions can limit what medications the patient can receive in ...

Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions.
https://doi.org/10.1016/j.clindermatol.2020.06.010
Clinics in Dermatology; Cheraghlou S, Levy LL

Dec 20th, 2020 - Drug reactions are among the most common reasons for inpatient dermatology consultation. These reactions are important to identify because discontinuation of the offending agent may lead to disease remission. With the rising use of immunomodulator...

A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883102
Dermatologic Therapy; Najar Nobari N, Seirafianpour F et. al.

Dec 10th, 2020 - Most of drugs could have certain mucocutaneous reactions and COVID-19 drugs are not an exception that we focused. We systematically reviewed databases until August 15, 2020 and among initial 851 articles, 30 articles entered this study (20 case re...

see more →

News  33 results

Genital Ulcers: Differential Diagnosis and Management
https://www.aafp.org/afp/2020/0315/p355.html
American Family Physician; Roett MA,et al

Mar 14th, 2020 - Genital ulcers may be located on the vagina, penis, and anorectal or perineal areas and may be infectious or noninfectious. Herpes simplex virus is the most common cause of genital ulcers in the United States. A diagnosis of genital herpes simplex...

Mogamulizumab prolongs PFS in CTCL
https://www.mdedge.com/hematology-oncology/article/184781/lymphoma-plasma-cell-disorders/mogamulizumab-prolongs-pfs-ctcl
HT Staff

Aug 14th, 2018 - Photo by Larry Young Youn Kim, MD Mogamulizumab is an effective treatment option for relapsed/refractory cutaneous T-cell lymphoma (CTCL), according to researchers. In the phase 3 MAVORIC trial, mogamulizumab prolonged progression-free survival (P.

Mogamulizumab is ‘valuable’ option for CTCL
https://www.mdedge.com/hematology-oncology/article/185146/lymphoma-plasma-cell-disorders/mogamulizumab-valuable-option-ctcl
Jen Smith

Feb 5th, 2018 - Photo by Larry Young Youn H. Kim, MD LA JOLLA, CA—Mogamulizumab is a valuable new therapeutic option for patients with cutaneous T-cell lymphoma (CTCL), according to researchers.

Levonorgestrel-Releasing Intrauterine System Causes a Lichenoid Drug Eruption
https://www.mdedge.com/dermatology/article/101017/dermatopathology/levonorgestrel-releasing-intrauterine-system-causes
Jennifer A. Jones Md, PhD, Marshall J. Shuler, MD et. al.

Jul 6th, 2015 - To the Editor: Numerous drugs have been implicated as possible causes of lichenoid drug eruptions (LDEs). We describe a case of an LDE secondary to placement of a levonorgestrel-releasing intrauterine system (IUS).

see more →